iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

November 17, 2017: By Jon Swedien

iVeenaiVeena Delivery Systems has successfully completed a pilot clinical trial for its lead product, IVMED-10, a bioerodible implant that treats pain and inflammation after cataract surgery, the Salt Lake City-based company announced Nov. 8.

IVMED-10 is a sustained release implant, based on the company’s intracapsular drug delivery platform, that delivers dexamethasone for two weeks. The device is placed in the lens capsule during the time of cataract surgery. It is intended for patients undergoing routine cataract extraction, iVeena said.

Eight patients were enrolled in the Phase I/IIa, single-site, single-arm, open-label clinical study. iVeena said an independent clinical trial report found IVMED-10 was safe and effective for the control of inflammation typically observed following cataract surgery. Retinal thickness outcomes were comparable to published data of nonsteroidal anti-inflammatory drugs and steroid standard of care therapy. All adverse events, including elevated intraocular pressure, corneal edema, and pain, were transient in nature. All patients had 20/25 best-corrected visual acuity or better at the end of the study, iVeena said.

iVeena has additional clinical studies of IVMED-10 planned for Q1-2018.

The company is also developing IVMED-20, a sustained release implant that delivers dexamethasone for six weeks. The product is placed in the lens capsule at the time of cataract surgery and is intended for patients that are at risk of developing retinal thickening in association with cataract extraction.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023